Document is current
Any future updates will be listed below
-
Authors
Teixeira, J. Pedro
Yessayan, Lenar
Tolwani, Ashita
Neyra, Javier
Reis, Thiago
- License Information
-
More Information
Article History
Received: 24 March 2026
Accepted: 6 May 2026
First Online: 11 May 2026
Declarations
:
: Not applicable.
: Not applicable.
: J. P. T. reports receiving consulting fees from Mallinckrodt, Outset Medical, and Vantive and ownership of publicly available stock and/or stock options in Eli Lilly, Novo Nordisk A/S, and Pfizer. L.Y. reports receiving consulting fees from Vantive. A. T. reports serving on a Speakers Bureau for Baxter; having a patent on a 0.5% trisodium citrate solution for CRRT anticoagulation (the license has been bought by Baxter); having consultancy agreements with Baxter Healthcare Inc.; and receiving honoraria from UpToDate. J.A.N. reports having consultancy agreements with Vantive and CovarsaDx. T. R. reports having no conflicts of interest to declare.
